Articles by: James Calvin

Sonus Networks Preliminary Q3 Sales

Sonus Networks Preliminary Q3 Sales

October 17, 2017 at 5:43 pm 0 comments

Sonus Networks (SONS) shares were halted on Friday after the company said preliminary results show total revenue is expected to be $74.5 million in Q3, compared with the company’s previous guidance range of $70 million to $72 million and an average analyst estimate of $70.8 million from Capital IQ. SONS shares are set to resume trading at 8 am ET.Read More

Coeur Mining Reports Improved Q3 Silver Equivalent Production But Lowers 2017 Guidance

Coeur Mining Reports Improved Q3 Silver Equivalent Production But Lowers 2017 Guidance

October 11, 2017 at 12:34 am 0 comments

Coeur Mining (CDE) reported late Thursday that Q3 production was 9.5 million silver equivalent ounces, comprised of 4.0 million silver ounces and 93,293 gold ounces. Q3 silver equivalent production increased 7% quarter-over-quarter and 10% year-over-year. The quarterly increase in silver equivalent production was driven by a 13% increase in gold production while higher year-over-year silver equivalent production was due toRead More

Acorda Therapeutics Receives Refusal to File Letter from FDA for Inbrija New Drug Application

Acorda Therapeutics Receives Refusal to File Letter from FDA for Inbrija New Drug Application

August 30, 2017 at 5:37 pm 0 comments

Acorda Therapeutics (ACOR) that it received a refusal to file (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for Inbrija. Inbrija is an investigational treatment for patients with Parkinson’s disease taking a carbidopa/levodopa regimen. Tne FDA determined that the NDA, submitted in June, was not sufficiently complete to permit a substantive review.Read More

Valeant Pharma Agrees to Divest Obagi Medical Products Business

Valeant Pharma Agrees to Divest Obagi Medical Products Business

July 17, 2017 at 4:45 pm 0 comments

Shares of Valeant Pharmaceuticals International (VRX) were barely higher pre-market Monday after the Canada-based drug maker said it agreed to sell its Obagi Medical Products business to Haitong International Zhonghua Finance Acquisiiton Fund I for $190 million in cash. The fund counts China Regenerative Medicine International as one of its limited partners. Valeant said it will use the proceeds fromRead More